Feasibility and efficacy of thrombolysis in acute ischemic stroke: A study from National Institute of Neurological and Allied Sciences, Kathmandu, Nepal

Lekhjung Thapa, Shikher Shrestha¹, Pratyush Shrestha¹, Suman Bhattarai, D. N. Gongal¹, U. P. Devkota¹

Departments of Neurology and Neurosurgery, National Institute of Neurological and Allied Sciences, Kathmandu, Nepal

ABSTRACT

Background: Stroke is the major cause of morbidity and mortality worldwide. The number of stroke patients receiving recombinant tissue plasminogen activator (rt-PA), also known as Alteplase, in the developing world is extremely low. We aim to study the feasibility and efficacy of thrombolysis for the 1st time in our country. Materials and Methods: In this retrospective study (July 2012-August 2015), acute ischemic stroke patients who were thrombolized within 3 h of stroke onset were included. Their demographic profiles, clinical profiles, risk factors, type of thrombolytic used, and outcomes were systematically recorded and analyzed. Results: A total of 9 patients were thrombolized. The mean time from the onset of stroke symptoms to first dose of rt-PA (onset to treatment) was 1.2 h. Six patients had good neurological outcome as measured by modified Rankin Scale (mRS). The median mRS at discharge was 3. Thrombolysis-related post treatment complication was noted in 44.4%, of which nonfatal intracranial bleed occurred only in 2 patients (22.2%). None of the patients receiving intravenous tenecteplase had thrombolysis-related complications, and none of the patients had fatal intracranial bleed. Conclusion: This study clearly demonstrates the beginning of a feasible and effective thrombolysis in the treatment of acute ischemic stroke in Nepal.

Key words: Ischemic stroke, Nepal, thrombolysis, tissue plasminogen activator

Introduction

In developing countries, the burden of cerebrovascular diseases has reached epidemic proportions over the past three decades.¹ According to WHO estimates, cerebrovascular disease was the cause of 107.5/100,000 deaths (age-standardized death rate) in Nepal.² Provision of recombinant tissue plasminogen activator (rt-PA) therapy in stroke victims within 3 h is an effective treatment with particularly good medium to long-term results. However, it is also known that there is high complication rate with rt-PA treatment versus placebo, particularly with the increased risk of cerebrovascular hemorrhage and an overall mortality of 17%.³ There is a reasonable amount of literature explaining the difficulties in providing rt-PA treatment in developing countries and the various barriers within these countries that lead to poor provision of thrombolysis.⁴,⁵ Because of this, provision of effective thrombolysis treatment within developing countries is rare⁶ and that which is offered is done so via the private sector.⁴,⁶ Thrombolysis in Nepal is currently available only in the private sector, primarily because of the great expenditure required to offer it on a public basis and partly because of lack of availability of a dedicated stroke team.

Address for correspondence:
Dr. Lekhjung Thapa, Department of Neurology, National Institute of Neurological and Allied Sciences, Kathmandu, Nepal.
E-mail: drlekhjung@gmail.com

Access this article online

Quick Response Code: www.ruralneuropactice.com
DOI: 10.4103/0976-3147.172161

How to cite this article: Thapa L, Shrestha S, Shrestha P, Bhattarai S, Gongal DN, Devkota UP. Feasibility and efficacy of thrombolysis in acute ischemic stroke: A study from National Institute of Neurological and Allied Sciences, Kathmandu, Nepal. J Neurosci Rural Pract 2016;7:55-60.
Materials and Methods

In this retrospective study from National Institute of Neurological and Allied Sciences (NINAS), relevant data of all the acute ischemic patients presenting to emergency department from June 2012 to August 2015 was collected. Ethical clearance was taken from the Institutional Review Board. All the patients who presented within 3 h of stroke onset and thrombolized were enrolled in our study. As per record, these patients were assessed by our acute stroke team for eligibility for thrombolysis and for appropriate case selection; standardized recommendation for inclusion and exclusion criteria was strictly followed [Table 1].[7] Informed written consents were taken from all the patients or their relatives. All the patients were thoroughly examined and computed tomography (CT) scan brain to rule out hematoma and magnetic resonance imaging stroke protocol to assess early infarct [Figure 1], salvageable tissue, and any evidence of cerebral arterial occlusion was done. Thrombolysis was carried out in Intensive Care Unit (ICU) as per standard protocol [Table 2].[7] Tenecteplase (TNK) was used at a dose of 0.25 mg/kg, administered as a single bolus, with a maximum dose of 25 mg.[8] All the patients’ demographic profiles, clinical profiles, risk factors for stroke, type of thrombolytic used, and outcomes as measured by modified Rankin Scale (mRS) and National Institute of Health Stroke Scale (NIHSS) when available were systematically recorded and analyzed.

Results

A total of 496 patients (317 males and 179 females) of acute stroke had attended emergency room from June 2014 to August 2015, of which 261 had ischemic stroke, 15 had transient ischemic stroke (TIA), 21 had lacunar infarct, 144 had hemorrhagic stroke, and 55 had subarachnoid hemorrhage.

Between 14th June 2012 and August 2015, 11 cases were thrombolized, of which 9 cases (3.4%) of acute ischemic stroke attending emergency ward of NINAS were thrombolized within 3 h. A total of 6 cases received intravenous (IV) rt-PA, 2 cases received IV TNK, and 1 received intra-arterial TNK.

Of 9 patients, 5 were males and 4 were females. Age ranged from 27 to 79 years (mean age 55.3). Among the risk factors, 4 patients (44.4%) had history of hypertension, 1 (11.1%) had previous TIA, 3 (33.3%) had rheumatic heart disease; of which 1 (11.1%) had atrial fibrillation and 1 (11.1%) had undergone commissurotomy for mitral stenosis. Two (22.2%) patients were alcoholic, and 1 (11.1%) patient was a smoker. All of the patients’ biochemical parameters were normal [Table 3].

The mean onset to treatment time was 1.2 h. Thrombolysis-related posttreatment complication was noted in 4 patients (44.4%), of which nonfatal intracranial

| Table 1: Inclusion and exclusion characteristics of patients with ischemic stroke who could be treated with IV rt-PA within 3 h from symptom onset |
|---------------------------------------------------------------|
| **Inclusion criteria**                                        |
| Diagnosis of ischemic stroke causing measurable neurological deficit |
| Onset of symptoms <3 h before beginning treatment            |
| Aged ≥ 18 years                                              |
| **Exclusion criteria**                                       |
| Significant head trauma or prior stroke in previous 3 months |
| Symptoms suggest subarachnoid hemorrhage                     |
| Arterial puncture at noncompressible site in previous 7 days |
| History of previous intracranial hemorrhage                  |
| Intracranial neoplasm, arteriovenous malformation, or aneurysm|
| Recent intracranial or intraspinal surgery                    |
| Elevated blood pressure (systolic >185 mm Hg or diastolic >110 mm Hg) |
| Active internal bleeding                                     |
| Acute bleeding diathesis, including but not limited to        |
| Platelet count <100,000/mm²                                   |
| Heparin received within 48 h, resulting in abnormally elevated aPTT greater than the upper limit of normal |
| Current use of anticoagulant with INR >1.7 or PT >15 s        |
| Current use of direct thrombin inhibitors or direct factor Xa inhibitors with elevated sensitive laboratory tests (such as aPTT, INR, platelet count, and ECT; TT; or appropriate factor Xa activity assays) |
| Blood glucose concentration <50 mg/dL (2.7 mmol/L)            |
| CT demonstrates multilobar infarction (hypodensity >1/3 cerebral hemisphere) |

Relative exclusion criteria

Recent experience suggests that under some circumstances—with careful consideration and weighting of risk to benefit-patients may receive fibrinolytic therapy despite 1 or more relative contraindications. Consider risk to benefit of IV rt-PA administration carefully if any of these relative contraindications are present

Only minor or rapidly improving stroke symptoms (clearing spontaneously)

Pregnancy

Seizure at onset with postictal residual neurological impairments

Major surgery or serious trauma within previous 14 days

Recent gastrointestinal or urinary tract hemorrhage (within previous 21 days)

Recent acute myocardial infarction (within previous 3 months)

Adapted from: Edward C. Jauch, Jeffrey L. Saver, Harold P. Adams, Askiel Bruno, J.J. (Buddy) Connors, Bart M. Demaerschalk et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2013;44:870-947.

rt-PA: Recombinant-tissue plasminogen activator; IV: Intravenous, aPTT: Activated partial thromboplastin time, INR: International normalized ratio, TT: Thrombin time, ECT: Ecarin clotting time, CT: Computed tomography
bleed occurred only in 2 patients (22.2%). None of the patients receiving IV TNK had thrombolyis-related complications, and none of the patients had fatal intracranial bleed. Six patients (66.6%) had good neurological outcome as measured by mRS or NIHSS. The median mRS at discharge was 3 [Table 4].

Discussion

Thrombolysis is one of the proven potential treatments for the management of acute ischemic stroke. For the 1st time in our country, we thrombolyzed 9 cases of acute ischemic stroke presenting within the window period of 3 h. Eight of our cases received IV thrombolysis while intra-arterial thrombolysis was done in 1 case of vertebrobasilar stroke. Stroke is known to be the leading cause of disability and mortality worldwide (5.7 million annual deaths). Although we get 8–10 cases of acute ischemic stroke per week at our institution, most of them reach us late and do not qualify for thrombolysis. Prehospital delay, financial constraints, and lack of infrastructure are main barriers of thrombolytic therapy. In Nepal, all the three problems including stroke awareness, transportation facility, and difficulty in easy access due to geographical factors do exist. To offer the best benefit to the patients, we have thrombolyzed patients beyond 3 h and have currently extended therapeutic window in our protocol up to 4.5 h. The mean age of patients we thrombolyzed was 55.3. Low- and middle-income countries like ours, where the average age of patients with stroke is 15 years younger, have high stroke burden. We used rt-PA in most of the cases, and it is the only medically approved biological treatment for acute ischemic stroke for use within 4.5 h of stroke onset and is recommended by most national and international stroke associations as a first-line therapy. After the result of NINDS trial, rt-PA has been widely used in United States and Europe. The safety and effectiveness of rt-PA have been proven at an IV dose of 0.9 mg/kg (10% bolus during 1 min and 90% infusion over 1 h) within 3 h in the United States and within 4.5 h of stroke onset in Europe. Although Japan Alteplase Clinical Trial study suggests a dose of 0.6 mg/kg for clinical efficacy and safety of Japanese patients, we used the dose recommended by Food and Drug Administration (FDA) and all of our patients receiving rt-PA received FDA-approved dose protocol. TNK, a newer thrombolytic agent, has been approved for the treatment of acute myocardial infarction and has given hope for the possibility of a much safer alternatives in acute ischemic stroke. Our initial encouraging results with rt-PA prompted us to use a more safer agent TNK because of mainly two reasons: (1) rt-PA was not imported by the pharmaceuticals because it was not used in the country as per their expectations and (2) TNK is widely used by cardiologists, easily available, and researches have proven it to be safer, effective, and easy to use in acute ischemic stroke patients. We had counseled both the patients and family members before administering TNK about their disease, therapeutic options, unavailability of rt-PA and the trial stage of the TNK, their results, and pending FDA approval for use in stroke. Interestingly, all three patients (case 7, 8, and 9) receiving TNK had an excellent recovery without any complications, and none of the patients had fatal intracranial bleed. Six patients (66.6%) had good neurological outcome as measured by mRS or NIHSS. The median mRS at discharge was 3 [Table 4].

Table 2: Treatment of acute ischemic stroke: IV administration of rt-PA

| Step                                                                 | Details                                                                 |
|----------------------------------------------------------------------|-------------------------------------------------------------------------|
| Infuse 0.9 mg/kg (maximum dose 90 mg) over 60 min, with 10% of the dose given as a bolus over 1 min | Admit the patient to an intensive care or stroke unit for monitoring if the patient develops severe headache, acute hypertension, nausea, or vomiting or has a worsening neurological examination, discontinue the infusion (if IV rtPA is being administered) and obtain emergent CT scan. Measure blood pressure and perform neurological assessments every 15 min during and after IV rtPA infusion for 2 h, then every 30 min for 6 h, then hourly until 24 h after IV rtPA treatment. Increase the frequency of blood pressure measurements if systolic blood pressure is >180 mm Hg or if diastolic blood pressure is >105 mm Hg; administer antihypertensive medications to maintain blood pressure at or below these levels. Delay placement of nasogastric tubes, indwelling bladder catheters, or intra-arterial pressure catheters if the patient can be safely managed without them. Obtain a follow-up CT or MRI scan at 24 h after IV rtPA before starting anticoagulants or antiplatelet agents. |
| Adapted from: Edward C. Jauch, Jeffrey L. Saver, Harold P. Adams, Askiel Bruno, J.J.(Buddy) Connors, Bart M. Demaerschalk et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2013;44:870-947. | rt-PA: Recombinant-tissue plasminogen activator, CT: Computed tomography, MRI: Magnetic resonance imaging, IV: Intravenous |
We had administered thrombolytic agents in ICU, set-up after ruling out all the contraindications [Table 4]. A prospective, nontrial, multicenter, observational study, SITS-ISTR (Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Registry) for 700 clinical centers practicing thrombolysis for acute stroke in 35 countries demonstrated the rate of symptomatic intracerebral hemorrhage of 1.6% at 3 h and 2.2% within 3–4.5 h; mortality rate of 12.2% at 3 h and 12.7% within 3–4.5 h, and functional independence of 56.3% at 3 h and 58.0% within 3–4.5 h.

Despite the fact that thrombolysis using rt-PA has a higher potential for a better outcome, it is underused in patients with acute ischemic stroke. The low rates of rt-PA use in acute stroke, lower patient education and perception of risk by physicians, [19] and first patient had a history of hypertension. Age, hypertension, diabetes mellitus, cerebral amyloid angiopathy, early ischemic signs CT, and volume of cerebral ischemic lesions on diffusion-weighted imaging are known potential factors related to rt-PA-related intracranial hemorrhage.

Nepal has not been able to introduce IV rt-PA which has been approved for more than a decade ago in developed countries, such as availability of trained personnel in Nepal is very less. However, few hospitals have studied risk factors, and most of them have been approved for more than a decade ago.

Table 3: Baseline clinical and laboratory profiles of the patients in order from case 1 to case 9

| HTN | DM | Hyper-lipidemia | TIA/stroke | RHD | AF | CMP | Alcohol | Smoking | Hb | TC | Platelets | INR | Urea | Creatinine | Na⁺ | K⁺ | Total cholesterol | TG | HDL | LDL |
|-----|----|----------------|------------|-----|----|-----|---------|---------|----|----|-----------|-----|------|------------|-----|-----|-----------------|----|-----|-----|
| +   | 0  | 0              | 0          | 0   | 0  | 0   | 0       | 0       | 11.2| 8100| 165,000   | 1   | 19   | 0.7        | 135 | 4.4| 130            | 108| 28 | 80 |
| 0   | 0  | 0              | 0          | 0   | 0  | +   | 0       | +       | 12  | 5600| 150,000   | 1   | 20   | 0.6        | 136 | 4.5| 120            | 112| 35 | 86 |
| +   | 0  | 0              | 0          | 0   | 0  | 0   | 0       | 0       | 14  | 8200| 167,000   | 1.2| 19   | 0.6        | 133 | 4.1| 135            | 111| 38 | 89 |
| +   | 0  | 0              | +          | 0   | 0  | 0   | 0       | 0       | 14.9| 6300| 217,000   | 1.2| 17   | 0.7        | 133 | 4  | 150            | 80 | 30 | 104|
| 0   | 0  | 0              | 0          | 0   | 0  | + (MS)| 0       | 0       | 14.1| 7500| 363,000   | 1.1| 20   | 0.8        | 134 | 4.2| 132            | 110| 32 | 90 |
| 0   | 0  | 0              | 0          | 0   | 0  | 0   | 0       | 0       | 14.6| 7200| 262,000   | 1.1| 15   | 0.8        | 135 | 3.8| 118            | 66 | 31 | 74 |
| 0   | 0  | 0              | 0          | 0   | 0  | 0   | +       | 0       | 11.5| 9300| 306,000   | 1.4| 26   | 0.7        | 138 | 4.2| 150            | 110| 36 | 86 |
| +   | 0  | 0              | 0          | 0   | 0  | 0   | 0       | +       | 15.1| 75,000| 160,000   | 1  | 19   | 0.6        | 140 | 3.9| 110            | 84 | 36 | 57 |
| +   | 0  | 0              | 0          | 0   | 0  | 0   | 0       | 0       | 16.3| 104,000| 223,000   | 1.1| 24   | 0.9        | 141 | 3.4| 132            | 110| 40 | 88 |

+: Present, 0: Absent, HTN: Hypertension, DM: Diabetes mellitus, TIA: Transient ischemic stroke, RHD: Rheumatic heart disease, MS: Mitral stenosis, AF: Atrial fibrillation, CMP: Cardiomyopathy, TG: Triglycerides, HDL: High-density lipoproteins, LDL: Low-density lipoproteins, Hb: Hemoglobin, TC: Total count, INR: International normalized ratio.
the burden of stroke is increasing day-by-day. The NINAS consists of a trained stroke team including neurologists, neuroradiologists, and neurosurgeons working around the clock, and hence thrombolysis can be easily performed within a defined period. However, rt-PA is not easily available in all the hospitals of Nepal and is a costly medicine (NPR 33,000/-[approximately 330 US dollars]), which might not be affordable for the general Nepalese population. Nevertheless, our report demonstrates and brings hope for the beginning of effective thrombolysis in the treatment of acute ischemic stroke in Nepal.

## Conclusion

Although our study has all the inherent limitations of a retrospective study, our report clearly demonstrates the beginning of a feasible and effective thrombolysis in the management of acute ischemic stroke in Nepal. This study indicates a landmark achievement for the country and will hopefully initiate the spread of wider reaching thrombolytic therapy for acute ischemic stroke across Nepal and developing countries.

## Acknowledgment

We would like to thank all the registrars, medical officers, and staff of NINAS for helping in timely patient management and data collection. We would also like to thank Mr. Shakti Shrestha and Mr. Ramesh Sharma Poudel for manuscript preparation. We thank Ms. Jana Hermann and Ms. Helen Jessie Uriah for English editing.

## Financial support and sponsorship

Nil.

## Conflicts of interest

There are no conflicts of interest.

## References

1. Dural Pandian J, Padma V, Vijaya P, Sylaja PN, Murthy JM. Stroke and thrombolysis in developing countries. Int J Stroke 2007;2:17-26.
2. Bhalla D, Marin B, Preux PM. Stroke profile in Afghanistan and Nepal. Neurrol Asia 2009;14:87-94.
3. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;323:167-78.
4. Ghanemshari K. Barriers of thrombolysis therapy in developing countries. Stroke Res Treat 2011;2011:68797.
5. Wasy M, Khatri IA, Kaul S. Stroke in South Asian countries. Nat Rev Neurol 2014;10:135-43.
6. Shuaib A, Mohammad A, Sherin A, Butcher K, Khan K, Tariq M, et al. Treatment of acute stroke: Is there a role for streptokinase when it is not available? J Postgrad Med Inst 2013;27:122-8.
7. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:970-947.
8. Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Mitaff F, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012;366:1099-107.
9. Intercollegiate Stroke Working Party (ISWP). National Clinical Guidelines for Stroke. 2nd ed. Suffolk: The Lavenham Press Ltd; 2010.
10. Jivan K, Ranchod K, Modi G. Management of ischemic stroke in the acute setting: Review of the current status. Cardiovasc J Afr 2013;24:86-92.
11. Donnan GA, Fisher M, Maclod M, Davis SM. Stroke. Lancet 2008;371:1612-23.
12. Wallgren N, Ahmed N, Daivalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): An observational study. Lancet 2007;369:275-82.
13. Blakeley JO, Llinas RH. Thrombolytic therapy for acute ischemic stroke. J Neurol Sci 2007;261:55-62.
14. Cohen DJ, Macdonald H. UK drug agency announces review of use of alteplase after stroke. BMJ 2014;349:g3555.
15. Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006;37:1810-5.
16. Scottish Intercollegiate Guidelines Network. Management of Patients with Stroke or TIA: Assessment, Investigation, Immediate Management and Secondary Prevention, a National Clinical Guideline. Number 108. Edinburgh: SIGN; 2008.
17. Nordt TK, Bode C. Thrombolysis: Newer thrombolytic agents and their role in clinical medicine. Heart 2003;89:1358-62.
18. Wahlgren N, Ahmed N, Dávalos A, Hacke W, Millán M, Muir K, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): An observational study. Lancet 2008;372:1303-9.
19. Larrue V, von Kummer R, del Zoppo G, Bluhmki E. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative acute stroke study. Stroke 1997;28:957-60.
20. Bambauer KZ, Johnston SC, Bambauer DE, Zivin JA. Reasons why few patients with acute stroke receive tissue plasminogen activator. Arch Neurol 2006;63:661-4.
21. Bobrow BJ, Demaerschalk BM, Wood JP, Villarin A, Clark I, Jennings A. Views of emergency physicians on thrombolysis for acute ischemic stroke. J Brain Dis 2009;1:29-37.
22. Shaik MM, Loo KW, Gan SH. Burden of stroke in Nepal. Int J Stroke 2012;7:517-20.